NO20072747L - Fremgangsmate for fremstilling av indazolforbindelser - Google Patents

Fremgangsmate for fremstilling av indazolforbindelser

Info

Publication number
NO20072747L
NO20072747L NO20072747A NO20072747A NO20072747L NO 20072747 L NO20072747 L NO 20072747L NO 20072747 A NO20072747 A NO 20072747A NO 20072747 A NO20072747 A NO 20072747A NO 20072747 L NO20072747 L NO 20072747L
Authority
NO
Norway
Prior art keywords
preparation
compounds
formula
indazole compounds
protein kinases
Prior art date
Application number
NO20072747A
Other languages
English (en)
Inventor
Bing Shi
Qingping Tian
Babu Srinivasan
Jr Raymond Dagnino
Michael Allen Ouelette
Scott Edward Zook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20072747L publication Critical patent/NO20072747L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Foreliggende oppfinnelsen angår fremgangsmåter for fremstilling av indasolforbindelser som har formel (I) eller farmasøytisk akseptable salter eller solvater derav. Forbindelser med formel (I) er anvendelige som antiangiogenesemidler og som midler for å modulere og/eller inhibere aktiviteten til proteinkinaser, som således tilveiebringer behandlinger for kreft eller andre sykdommer assosiert med cellulær proliferasjon mediert av proteinkinaser.
NO20072747A 2004-11-02 2007-05-30 Fremgangsmate for fremstilling av indazolforbindelser NO20072747L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02
PCT/IB2005/003300 WO2006048745A1 (en) 2004-11-02 2005-10-21 Methods for preparing indazole compounds

Publications (1)

Publication Number Publication Date
NO20072747L true NO20072747L (no) 2007-07-31

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072747A NO20072747L (no) 2004-11-02 2007-05-30 Fremgangsmate for fremstilling av indazolforbindelser

Country Status (15)

Country Link
EP (1) EP1809625A1 (no)
JP (1) JP2008518901A (no)
KR (1) KR20070058689A (no)
CN (1) CN101044138A (no)
AR (1) AR051753A1 (no)
AU (1) AU2005300311A1 (no)
BR (1) BRPI0517921A (no)
CA (1) CA2586176A1 (no)
IL (1) IL182096A0 (no)
MX (1) MX2007003603A (no)
NO (1) NO20072747L (no)
RU (1) RU2007114112A (no)
TW (1) TW200614990A (no)
WO (1) WO2006048745A1 (no)
ZA (1) ZA200702317B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP4249063A3 (en) 2007-04-05 2024-03-13 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
WO2013046133A1 (en) 2011-09-30 2013-04-04 Pfizer Inc. Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
BR112014011453A2 (pt) 2011-11-11 2017-05-02 Pfizer n-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida para o tratamento de leucemia mielógena crônica
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN103387565B (zh) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 阿西替尼的制备方法
CN103570696B (zh) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
WO2015119930A1 (en) 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CA2942888C (en) * 2014-03-31 2021-09-07 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
CN104072484B (zh) * 2014-07-07 2016-07-06 渤海大学 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent GmbH Pd-l1 antagonist combination treatments
AU2017339856B2 (en) 2016-10-06 2024-09-05 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EA202192731A1 (ru) 2019-04-18 2022-02-04 Синтон Б.В. СПОСОБ ПОЛУЧЕНИЯ АКСИТИНИБА, СПОСОБ ОЧИСТКИ ПРОМЕЖУТОЧНОГО СОЕДИНЕНИЯ 2-((3-ЙОД-1H-ИНДАЗОЛ-6-ИЛ)ТИО)-N-МЕТИЛБЕНЗАМИДА, СПОСОБ ОЧИСТКИ АКСИТИНИБА ЧЕРЕЗ HCl СОЛЬ АКСИТИНИБА, ТВЕРДАЯ ФОРМА HCl СОЛИ АКСИТИНИБА
CN112209861A (zh) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 一种阿昔替尼中间体化合物及其制备方法
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用
CN111440102B (zh) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 一种二硫代二苯甲酰胺类化合物的制备方法
AU2023228391A1 (en) 2022-03-03 2024-09-19 Pfizer Inc. Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
WO2024032584A1 (zh) * 2022-08-08 2024-02-15 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其医疗用途
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
PL377713A1 (pl) * 2002-12-19 2006-02-06 Pfizer Inc. Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
JP4617299B2 (ja) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
JPWO2005094823A1 (ja) * 2004-03-30 2007-08-16 協和醗酵工業株式会社 Ｆｌｔ−３阻害剤

Also Published As

Publication number Publication date
CA2586176A1 (en) 2006-05-11
WO2006048745A1 (en) 2006-05-11
CN101044138A (zh) 2007-09-26
BRPI0517921A (pt) 2008-10-21
IL182096A0 (en) 2007-07-24
MX2007003603A (es) 2007-05-21
AU2005300311A1 (en) 2006-05-11
TW200614990A (en) 2006-05-16
ZA200702317B (en) 2008-09-25
EP1809625A1 (en) 2007-07-25
JP2008518901A (ja) 2008-06-05
KR20070058689A (ko) 2007-06-08
AR051753A1 (es) 2007-02-07
RU2007114112A (ru) 2008-12-10

Similar Documents

Publication Publication Date Title
NO20072747L (no) Fremgangsmate for fremstilling av indazolforbindelser
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20081454L (no) Met-kinaseinhibitorer
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
NO20061743L (no) Kinazolinderivater
NO20064895L (no) 6,6-Bisykliske ring-substituerte heterobisykliske protein-kinase inhibitorer
NO20061194L (no) Mitotiske kinesininbibitorer
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20061327L (no) Kinazolinderivater
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
YU84603A (sh) Novi inhibitori tirozin kinaze
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
NO20091708L (no) Nye kinase inhibitorer
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
NO20083013L (no) Triazolopyridaziner som tyrosinkinasemodulatorer
NO20075992L (no) Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
NO20091605L (no) Pyridinonforbindelser
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application